Form 4: Nurix Therapeutics CFO Hans van Houte Executes Stock Transactions to Cover Tax Obligations

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, executed multiple transactions involving the vesting and sale of company stock to cover tax obligations.

Summary

• Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, engaged in several transactions on January 30, 2025.
• These transactions included the vesting of 8,636 restricted stock units (RSUs) which converted into common stock.
• A total of 2,811 shares were sold to cover tax withholding obligations related to the vesting of these RSUs.
• The sales were executed at weighted average prices of $19.8068 and $20.3256 per share.
• Following these transactions, Mr. van Houte directly owns 39,549 shares of Nurix Therapeutics common stock and 55,295 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation. While not inherently positive or negative, it indicates that the company is operating as expected with its equity incentive plans.

Positives

• The vesting of RSUs indicates that performance milestones were likely met.
• The 'sell to cover' mechanism ensures tax obligations are met without requiring personal funds from the executive.

Risks

• The sale of shares, even for tax purposes, could be perceived negatively by some investors if not understood.
• The price at which the shares were sold could be seen as a benchmark for the stock's value at the time of the transaction.

Industry Context

This type of transaction is common for executives who receive equity compensation, particularly in the biotechnology sector where stock options and RSUs are frequently used.

Comparison to Industry Standards

• Many biotechnology companies use restricted stock units as part of their compensation packages.
• The 'sell to cover' method for tax obligations is a standard practice in the industry.
• Similar transactions are regularly reported by executives at comparable companies such as Gilead Sciences and Amgen.

Stakeholder Impact

• Shareholders may be interested in the details of executive compensation and stock transactions.
• The transactions have a minor impact on the overall share float.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Form 4, Hans van Houte, CFO, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Equity Incentive Plan